Tiagabine: A novel antiepileptic drug

Annals of Pharmacotherapy

Volumn 32, Issue 11, 1998, Pages 1173-1180

  Luer, Mark S ^a   Rhoney, Denise H ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Epilepsy; Nipecotic acid; Tigagabine

Indexed keywords

CYTOCHROME P450 ISOENZYME; TIAGABINE;

4 AMINOBUTYRIC ACID UPTAKE; ADVERSE DRUG REACTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FOCAL EPILEPSY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0031785131     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18053     Document Type: Review

References (48)

1. Camfield PR, Camfield CS, Smith EC, Tibbles JA. Newly treated childhood epilepsy: a prospective study of recurrences and side effects. Neurology 1985;35:722-5.
2. Reynolds EH. Early treatment and prognosis of epilepsy. Epilepsia 1987; 28:97-106.
3. Elwes RDC, Johnson AL, Shorvon SD, Reynolds EH. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984;311: 944-7.
4. F-D-C Rep. The Pink Sheet 1997;59(40):6-7.
5. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995;36(suppl 6):S7-9.
6. Croucher MJ, Meldrum BS, Krogsgaard-Larsen P. Anticonvulsant activity of GABA uptake inhibitors and their prodrugs following central or systemic administration. Eur J Pharmacol 1983;89:217-28.
7. Shinnar S. Tiagabine. Semin Pediatr Neurol 1997;4:24-33.
8. Package insert. Gabitril (tiagabine hydrochloride). Chicago: Abbott Laboratories. Revised October 1997.
9. Braestrup C, Nielsen EB, Sonnewald U, Knutsen LJS, Andersen KE, Jansen JA, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl] nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake carrier. J Neurochem 1990;54:639-47.
10. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:612-26.
11. Borden LA, Murali Dhar TG, Smith KE, Weinshank RL, Branchek TA, Gluchowski C, et al. Tiagabine, SKF 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994;269:219-24.
12. Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992;220:197-201.
13. During M, Mattson R, Scheyer R, Rask C, Pierce M, McKelvy J, et al. The effect of tiagabine HCl on extracellular GABA levels in the human hippocampus (abstract). Epilepsia 1992;33(suppl 3):83.
14. Østergaard LH, Gram L, Dam M. Potential antiepileptic drugs. Tiagabine. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:1057-61.
15. Mengel H. Tiagabine. Epilepsia 1994;35(suppl 5):S81-4.
16. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995;36(suppl 6):S2-6.
17. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-11.
18. Gustavson LE, Mengel HB, Pierce MW, Cha SY. Tiagabine, a new γ-aminobutyric acid uptake inhibitor after single oral doses in man (abstract). Epilepsia 1990;31:642.
19. Jansen JA, Oliver S, Dirach J, Mengel HB. Absolute bioavailability of tiagabine (abstract). Epilepsia 1995;36(suppl 3):S159.
20. Mengel H, Gustavson LE, Soerensen HJ, McKelvy JF, Pierce MW, Houston A. Effect of food on the bioavailability of tiagabine (abstract). Epilepsia 1991;32(suppl 3):6.
21. Lau AL, Gustavson LE, Sperelakis R, Lam NP, El-Shourbagy T, Qian JX, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997;38:445-51.
22. Gustavson LE, Cato A, Guenther JH, Carlson GF, Witt GF, Cao GX, et al. Lack of clinically important drug interactions between tiagabine and carbamazepine, phenytoin, or valproate (abstract). Epilepsia 1995;36 (suppl 3):S159-60.
23. 14C-tiagabine in humans (abstract). Epilepsia 1992;33(suppl 3):83.
24. 14C]tiagabine by human hepatic micro-somes (abstract). Epilepsia 1995;36(suppl 3):S159.
25. Snel S, Mukherjee S, Richens A, Mengel HB. Pharmacokinetics of tiagabine in the elderly (abstract). Epilepsia 1993;34(suppl 2):157.
26. Cato A, Qian JX, Gustavson LE, Carlson GF, Witt GF, Cao GX, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of renal function. Epilepsia 1995;36(suppl 3):S159.
27. Gustavson LE, Boellner SW, Granneman GR, Qian JX, Guenther HJ, El-Shourbagy T, et al. A single-dose study to define the tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997;48:1032-7.
28. So EL, Wolff D, Graves NM, Leppik IE, Cascino GD, Pixton GC, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995;22:221-6.
29. Richens A, Gustavson LE, McKelvy JF, Mengel H, Deaton R, Pierce MW. Pharmacokinetics and safety of single-dose tiagabine HCl in epileptic patients chronically treated with four other antiepileptic drug regimens (abstract). Epilepsia 1991;32(suppl 3):12.
30. Mengel H, Jansen JA, Sommerville K, Jonkman JHG, Wesnes K, Cohen A, et al. Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol (abstract). Epilepsia 1995;36(suppl 3):S160.
31. Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994;4:141-50.
32. Thompson MS, Groes L, Schwietert HR, Jonkman JHG, Wemer J, Andreasen T, et al. An open label sequence listed two period crossover pharmacokinetic trial evaluating the possible interaction between tiagabine and erythromycin during multiple administration to healthy volunteers (abstract). Epilepsia 1997;38(suppl 3):64.
33. Richens A, Chadwick DW, Duncan JS, Dam M, Gram L, Mikkelsen M, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:37-42.
34. Sachdeo RC, Leroy RF, Krauss GL, Drake ME Jr, Green PM, Leppik IE, et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. Arch Neural 1997;54:595-601.
35. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995;36(suppl 6):S14-21.
36. Boellner SW, McCarty J, Mercante D, Sommerville K. Pilot study of tiagabine in children with partial seizures (abstract). Epilepsia 1996;37 (suppl 4):92.
37. Uldall P, Bulteau C, Pederson SA, Dulac O, Meinild H, Lassen LC. Single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy (abstract). Epilepsia 1995;36(suppl 3):S147-8.
38. Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995;36(suppl 6):S2-6.
39. Steinbjomsdottir S, Sander JWAS, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3:29-35.
40. Riekkinen PJ, Kälviäinen R, Äikiä M, Mervaala E, Saukkonen AM, Pitkänen A. Cognitive and electrophysiological effects of tiagabine add-on therapy: a randomized double-blinded placebo-controlled study (abstract 774S). Neurology 1994;44(suppl 2):A321.
41. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025-31.
42. Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 1996;5:153-6.
43. Marsen AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.
44. Elferink AJA, Van Zwieten-Boot BJ. Analysis based on number needed to treat shows differences between drugs studied. BMJ 1996;314:603.
45. Finkel AS, Hammond JM, Karlin DS, Morris S, Petropoulos M, Rosenberg J, et al., eds. 1997 Drug Topics Red Book. Montvale, NJ: Medical Economics Co., Inc., November 1997, Update;36.
46. Marsen AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313:1169-74.
47. Garnett WR. New opportunities for the treatment of epilepsy. Am J Health-Syst Pharm 1995;52:88-91.
48. Pashko S, McCord A, Sena MM. The cost of epilepsy and seizures in a cohort of Pennsylvania Medicaid patients. Med Interface 1993;(Nov):79-84.